Pelion Pharma Investment Programme (EBRD-50384)

Regions
  • Europe and Central Asia
Where the impacts of the investment may be experienced.
Countries
  • Poland
Where the impacts of the investment may be experienced.
Financial Institutions
  • European Bank for Reconstruction and Development (EBRD)
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
Project Status
Active
Bank Risk Rating
B
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Voting Date
Apr 9, 2019
The estimate day the bank will vote on a proposed investment. The decision dates may change, so review updated project documents or contact the EWS team.
Borrower
Korporacja Inwestycyjna Polskiej Farmacji Sp. z.o.o.
The holder of the loan, grant, or other investment.
Sectors
  • Finance
The service or industry focus of the investment. A project can have several sectors.
Investment Type(s)
Loan
The categories of the bank investment: loan, grant, etc.
Investment Amount (USD)
$ 53.62 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Currency conversion note:
Bank reported 200
Converted using 2019-06-24 exchange rate.
Project Cost (USD)
$ 73.86 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please see updated project documentation for more information.
Currency conversion note:
Bank reported 275.5
Converted using 2019-06-24 exchange rate.
Primary Source

Original disclosure @ EBRD website

Updated in EWS Jul 5, 2019

Disclosed by Bank Jun 24, 2019


Contribute Information
Can you contribute information about this project?
Contact the EWS Team

Project Description

According to the Bank's website, this project provides financing to Korporacja Inwestycyjna Polskiej Farmacji Sp. z o.o. for on-lending to Pelion SA and its subsidiaries to fund an investment programme across the group. 

The project aims to improve the logistic processes of this pharma group, facilitate market expansion and finance new types of pharmaceutical products. 

Investment Description
  • European Bank for Reconstruction and Development (EBRD)
Private Actors

Korporacja Inwestycyjna Polsiej Farmacji Sp. z o.o. is a holding company for Pelion which has successfully operated on both wholesale and retail pharma markets in Poland since 1990. The implementing company is fully owned by Mr. Jacek Szwajcowski and Mr. Zbigniew Molenda I; the founders of Pelion.

Contact Information

Management Office
biuro_zarzadu@kipf.pl
+48 42 200 75 10
pelion.eu

ACCOUNTABILITY MECHANISM OF EBRD

The Project Complaint Mechanism (PCM) is the independent complaint mechanism and fact-finding body for people who have been or are likely to be adversely affected by an European Bank for Reconstruction and Development (EBRD)-financed project. If you submit a complaint to the PCM, it may assess compliance with EBRD's own policies and procedures to prevent harm to the environment or communities or it may assist you in resolving the problem that led to the complaint through a dialogue with those implementing the project. Additionally, the PCM has the authority to recommend a project be suspended in the event that harm is imminent. You can contact the PCM at pcm@ebrd.com or you can submit a complaint online using an online form, http://www.ebrd.com/eform/pcm/complaint_form?language=en. You can learn more about the PCM and how to file a complaint at http://www.ebrd.com/work-with-us/project-finance/project-complaint-mechanism.html.